Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats

International Journal of Pharmaceutics

Volumn 400, Issue 1-2, 2010, Pages 124-130

  Katsumi, Hidemasa ^a   Nakatani, Maria ^a   Sano, Jun ichi ^a   Abe, Mari ^a   Kusamori, Kosuke ^a   Kurihara, Maki ^a   Shiota, Rika ^a   Takashima, Miki ^a   Fujita, Takuya ^a,c   Sakane, Toshiyasu ^a   Hibi, Toru ^b   Yamamoto, Akira ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b NEC Corporation of America   (United States)

^c RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

Alendronate; Bisphosphonates; Bone diseases; Intrapulmonary administration; Pulmonary absorption

Indexed keywords

ALENDRONIC ACID; CALCIUM; DIHYDROXYCOLECALCIFEROL; LACTATE DEHYDROGENASE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MASS; CALCIUM BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; HYPERCALCEMIA; LUNG LAVAGE; MALE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT MUCOSA;

ALENDRONATE; ANIMALS; BIOLOGICAL AVAILABILITY; BONE DENSITY CONSERVATION AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CALCIUM; DRUG DELIVERY SYSTEMS; FEMALE; L-LACTATE DEHYDROGENASE; LUNG; MALE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SUPEROXIDE DISMUTASE; TISSUE DISTRIBUTION;

EID: 77957669507     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.08.041     Document Type: Article

References (36)

1. Azuma Y., Sato H., Oue Y., Okabe K., Ohta T., Tsuchimoto M., Kiyoki M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16:235-245.
2. Bowie A., O'Neill L.A. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. 2000, 59:13-23.
3. Choi A., Gang H., Chun I., Gwak H. The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. Int. J. Pharm. 2008, 357:126-131.
4. Cocquyt V., Kline W.F., Gertz B.J., Van Belle S.J., Holland S.D., DeSmet M., Quan H., Vyas K.P., Zhang K.E., De Grève J., Porras A.G. Pharmacokinetics of intravenous alendronate. J. Clin. Pharmacol. 1999, 39:385-393.
5. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 2008, 83:1032-1045.
6. Enna S.J., Schanker L.S. Absorption of saccharides and urea from the rat lung. Am. J. Physiol. 1972, 222:409-414.
7. Ezra A., Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv. Drug Deliv. Rev. 2000, 42:175-195.
8. Fleisch H. Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin. Orthop. Relat. Res. 1987, 217:72-78.
9. Gafni R.I., McCarthy E.F., Hatcher T., Meyers J.L., Inoue N., Reddy C., Weise M., Barnes K.M., Abad V., Baron J. Recovery from osteoporosis through skeletal growth: early bone mass acquisition has little effect on adult bone density. FASEB J. 2002, 16:736-738.
10. Graham D.Y. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig. Dis. Sci. 2002, 47:1665-1678.
11. He L., Gao Y., Lin Y., Katsumi H., Fujita T., Yamamoto A. Improvement of pulmonary absorption of insulin and other water-soluble compounds by polyamines in rats. J. Control. Release 2007, 122:94-101.
12. Janner M., Mühlbauer R.C., Fleisch H. Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif. Tissue Int. 1991, 49:280-283.
13. Kamatari M., Koto S., Ozawa N., Urao C., Suzuki Y., Akasaka E., Yanagimoto K., Sakota K. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J. Bone Miner. Metab. 2007, 25:302-309.
14. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., Beneton M.N., Gertz B.J., Sciberras D.G., Holland S.D., Orgee J., Coombes G.M., Roger S.R., Porras A.G. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 1997, 12:1700-1707.
15. Koltover V.K. Bioantioxidants: the systems reliability standpoint. Toxicol. Ind. Health 2009, 25:295-299.
16. Kusamori, K., Katsumi, H., Abe, M., Ueda, A., Sakai, R., Hayashi, R., Hirai, Y., Quan, Y.S. Kamiyama, F., Sakane, T. Yamamoto, A., 2010. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. J. Bone. Miner. Res., doi:10.1002/jbmr.147.
17. Lambrinoudaki I., Christodoulakos G., Botsis D. Bisphosphonates. Ann. N.Y. Acad. Sci. 2006, 1092:397-402.
18. Lichtenberger L.M., Romero J.J., Gibson G.W., Blank M.A. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig. Dis. Sci. 2000, 45:1792-1801.
19. Lin J.H., Chen I.W., Duggan D.E. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab. Dispos. 1992, 20:473-478.
20. Morita T., Yamamoto A., Hashida M., Sezaki H. Effects of various absorption promoters on pulmonary absorption of drugs with different molecular weights. Biol. Pharm. Bull. 1993, 16:259-262.
21. Naniwa T., Maeda T., Mizoshita T., Hayami Y., Watanabe M., Banno S., Ito R. Alendronate-induced esophagitis: possible pathogenic role of hypersensitivity to alendronate. Intern. Med. 2008, 47:2083-2085.
22. Patton J.S., Bukar J., Nagarajan S. Inhaled insulin. Adv. Drug Deliv. Rev. 1999, 35:235-247.
23. Porras A.G., Holland S.D., Gertz B.J. Pharmacokinetics of alendronate. Clin. Pharmacokinet. 1999, 36:315-328.
24. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner. Res. 1990, 5:31-40.
25. Schanker L.S., Mitchell E.W., Brown R.A. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab. Dispos. 1986, 14:79-88.
26. Schenk R., Eggli P., Fleisch H., Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif. Tissue Int. 1986, 38:342-349.
27. Sener G., Goren F.O., Ulusoy N.B., Ersoy Y., Arbak S., Dülger G.A. Protective effect of melatonin and omeprazole against alendronate-induced gastric damage. Dig. Dis. Sci. 2005, 50:1506-1512.
28. Sener G., Paskaloglu K., Kapucu C., Cetinel S., Contuk G., Ayanog lu-Dulger G. Octreotide ameliorates alendronate-induced gastric injury. Peptides 2004, 25:115-121.
29. Sener G., Sehirli O., Cetinel S., Midillioĝlu S., Gedik N., Ayanoĝlu-Dülger G. Protective effect of taurine against alendronate-induced gastric damage in rats. Fundam. Clin. Pharmacol. 2005, 19:93-100.
30. Sutton S.C., Engle K., Fix J.A. Intranasal delivery of the bisphosphonate alendronate in the rat and dog. Pharm. Res. 1993, 10:924-926.
31. Van Beek E.R., Cohen L.H., Leroy I.M., Ebetino F.H., Löwik C.W., Papapoulos S.E. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003, 33:805-811.
32. Wong J.A., Renton K.W., Crocker J.F., O'Regan P.A., Acott P.D. Determination of pamidronate in human whole blood and urine by reversed-phase HPLC with fluorescence detection. Biomed. Chromatogr. 2004, 18:98-101.
33. Xiang A., Kanematsu M., Mitamura M., Kikkawa H., Asano S., Kinoshita M. Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice. Invest. Radiol. 2006, 41:704-712.
34. 1.7]-eel calcitonin from various mucosal administration sites. J. Control. Release 2001, 76:363-374.
35. Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 1978, 6:547-558.
36. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 1981, 4:879-885.